BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 23597965)

  • 1. Erdheim-Chester disease.
    Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
    Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
    Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erdheim-Chester disease.
    Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
    Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erdheim-Chester disease.
    Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
    Curr Rheumatol Rep; 2014 Apr; 16(4):412. PubMed ID: 24532298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
    Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
    Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erdheim-Chester disease involving the breast--a rare but important differential diagnosis.
    Guo S; Yan Q; Rohr J; Wang Y; Fan L; Wang Z
    Hum Pathol; 2015 Jan; 46(1):159-64. PubMed ID: 25454479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cytologic diagnosis of BRAF
    Chasseur P; Kyriakopoulou M; Vokaer B; Beukinga I; Casado Arroyo R; Cogan E; Couturier B
    Acta Clin Belg; 2017 Oct; 72(5):369-371. PubMed ID: 28222655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Understanding and Management of Erdheim-Chester Disease.
    Kulkarni AM; Gayam PKR; Aranjani JM
    Life Sci; 2024 Jul; 348():122692. PubMed ID: 38710283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erdheim-Chester Disease: a comprehensive review of the literature.
    Mazor RD; Manevich-Mazor M; Shoenfeld Y
    Orphanet J Rare Dis; 2013 Sep; 8():137. PubMed ID: 24011030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Erdheim-Chester disease].
    Mazor RD; Shoenfeld Y
    Harefuah; 2014 Jul; 153(7):389-91, 434, 433. PubMed ID: 25189027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multisystem Erdheim-Chester disease presenting with pericardial effusion confirmed by the effusion cytology specimen.
    Dai S; Su X; Liu WP; Wu Y
    Cardiovasc Pathol; 2024; 70():107625. PubMed ID: 38417471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of targeting therapy in Erdheim-Chester disease: A case report with neurologic involvement].
    Berthe P; Rouzic N; Daelman L; Jacobzone C; Espitia A; Cohen-Aubart F; Haroche J; Émile JF; Lorleac'h A
    Rev Med Interne; 2020 Jun; 41(6):413-417. PubMed ID: 32113636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients.
    Haroche J; Amoura Z; Trad SG; Wechsler B; Cluzel P; Grenier PA; Piette JC
    Arthritis Rheum; 2006 Oct; 54(10):3330-6. PubMed ID: 17009306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
    Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular involvement in Erdheim-Chester syndrome: clinical and therapeutic implications].
    Lauretta L; Dagna L; Alberti L; Loiacono F; De Cobelli F; Sanvito F; Moriggia S; Margonato A; Fragasso G
    Recenti Prog Med; 2013 Dec; 104(12):637-42. PubMed ID: 24362833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Amoura Z
    Blood; 2020 Apr; 135(16):1311-1318. PubMed ID: 32107533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saving orphans: BRAF targeting of histiocytosis.
    Heaney ML
    Blood; 2013 Feb; 121(9):1487-8. PubMed ID: 23449613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].
    Dasdelen S; Büschek F
    Internist (Berl); 2020 Sep; 61(9):969-979. PubMed ID: 32785740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.